Fact checks · Repurposed drugs
“Can metformin plus clemastine repair myelin and reverse MS disability?”
The bottom line
Early trials show small changes in visual-pathway repair markers, but metformin plus clemastine has not demonstrated reversal of MS disability and should not be self-prescribed.
Why people are talking about it
Laboratory research suggested that clemastine could encourage myelin-forming cells to mature and that metformin might restore responsiveness in aging precursor cells. Because these are existing medicines, conference announcements and media coverage have encouraged hopes for a readily available repair treatment.
What the research says
ReBUILD, published in 2017, was a 150-day double-blind randomized crossover trial of clemastine alone (not metformin plus clemastine) in 50 people with relapsing MS and chronic optic-pathway damage. Clemastine shortened visual evoked potential latency, an electrical signal-timing measure, by about 1.7 milliseconds per eye, supporting a possible repair effect without establishing disability reversal. The relevant combination trial is CCMR-Two, registered as NCT05131828. A corresponding published combination trial called ReSPOND could not be verified. CCMR-Two randomized 70 people with relapsing MS on disease-modifying treatment to the combination or placebo for six months. Results presented at ECTRIMS 2025 and described in institutional and MS Society reports showed a small improvement in signal timing, but no demonstrated improvement in visual function or disability. Those reports should not be represented as a full peer-reviewed results paper. Separately, a 2025 publication from the small, nonrandomized TRAP-MS clemastine arm reported accelerated disability accumulation in progressive MS and stopping of that arm after three of nine participants met safety-stopping criteria.
What we don't know yet
It is unknown whether the small biomarker changes translate into durable protection of nerves or meaningful improvements in daily life. Full combination-trial reporting, larger confirmatory studies and careful assessment across different MS populations are needed.
Risks and costs
Clemastine can cause drowsiness, fatigue and anticholinergic effects, while metformin can cause gastrointestinal problems and requires assessment of kidney function and other contraindications. The TRAP-MS findings raise a specific safety concern in progressive disease, although that small study does not establish the same risk for the combination in relapsing MS. Off-label prescriptions, monitoring and attempts to obtain medicines independently can add expense without established clinical benefit. These experimental repair approaches must not replace a proven disease-modifying therapy. CCMR-Two studied the combination alongside ongoing treatment.
Questions to bring to your neurologist
- Is there an appropriate remyelination trial I could join rather than taking these medicines off-label?
- How should the TRAP-MS safety findings affect decisions for my type and stage of MS?
- What evidence would show meaningful functional benefit rather than only a change in a repair biomarker?
Sources
- Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial (RCT, 2017)
- CCMR Two: A Phase IIa, Randomised, Double-blind, Placebo-controlled Trial of Metformin and Clemastine (Registry, 2021)
- Trial results suggest drug combo could boost myelin repair in relapsing MS (Report, 2025)
- Clemastine fumarate accelerates accumulation of disability in progressive multiple sclerosis by enhancing pyroptosis (Observational, 2025)
This is information, not medical advice. Talk to your neurologist before changing anything.
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error